Journal of diabetes and its complications最新文献

{"title":"The impact of glycemic variability on the 28-day prognosis of patients with cardiogenic shock with or without diabetes mellitus: A retrospective cohort study","authors":"Jing Tian ,&nbsp;Chenming Zhao,&nbsp;Yulu Li,&nbsp;Yi Han","doi":"10.1016/j.jdiacomp.2025.109151","DOIUrl":"10.1016/j.jdiacomp.2025.109151","url":null,"abstract":"<div><div>Glycaemic variability (GV) may reflect sharp rises and acute fluctuations in blood glucose, which are associated with adverse cardiovascular events. The aim of this study was to investigate the effect of GV on 28-day outcome in patients with cardiogenic shock (CS) with or without diabetes mellitus (DM).</div></div><div><h3>Methods</h3><div>This retrospective cohort study adhered to the RECORD (REporting of studies Conducted using Observational Routinely-collected Data) guidelines. We used clinical data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. GV was assessed using the coefficient of variation of blood glucose levels and statistically analysed by dividing patients into three groups according to GV tertiles (GV1, GV2 and GV3), with a primary outcome of 28-day prognosis and secondary outcomes of mechanical ventilation status, length of hospital stay and length of ICU stay.</div></div><div><h3>Results</h3><div>A total of 1091 patients from the MIMIC-IV database with CS were included, of which a total of 409 (37.49 %) were male patients and 682 (62.51 %) were female patients. Based on GV levels, three groups were classified as GV1 (&lt;16.2 %, <em>n</em> = 318), GV2 (16.2 %–25.3 %, <em>n</em> = 388), and GV3 (&gt;25.3 %, <em>n</em> = 385). According to the Kaplan-Meier curves, the 28-day prognosis was significantly better in GV1 patients than in GV3 [220 (69.2 %) vs. 234 (60.8 %), <em>P</em> = 0.044], and the same was true in the Non-DM subgroup [188 (73.7 %) vs. 108 (61.4 %), <em>P</em> = 0.016]. In a multifactorial COX analysis, GV was significantly associated with the risk of 28-day mortality in patients [HR 1.42, 95 % CI 1.10–1.60, <em>P</em> = 0.012]. In the subgroup analyses, the risk of death was highest in the DM subgroup of patients with GV3 (HR: 1.53, <em>p</em> = 0.003).</div></div><div><h3>Conclusion</h3><div>GV significantly increases the 28-day risk of death in patients with CS, especially in DM patients. Future optimisation of glucose monitoring techniques and exploration of GV modulation strategies are needed to improve patient prognosis.</div><div><strong>What is known about this research topic:</strong></div><div>Glycaemic variability (GV) significantly increases the 28-day risk of death in patients with cardiogenic shock (CS).</div><div>GV level (16.2 %–25.3 %) was an independent risk factor for 28-day mortality in patients with DM and CS, and GV (&gt;25.3 %) was an independent risk factor for 28-day mortality in Non-DM patients with CS.</div><div><strong>What this study adds and its future implications:</strong></div><div>More optimal glucose monitoring techniques and GV modulation strategies need to be refined to improve patient outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109151"},"PeriodicalIF":3.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pericardial fat pad detected on chest X-ray is closely associated with metabolic dysfunction-associated steatotic liver disease and visceral fat accumulation in patients with type 2 diabetes","authors":"Kentaro Watanabe,&nbsp;Hidenori Nishioka,&nbsp;Masahiro Takubo,&nbsp;Minami Kosuda,&nbsp;Takeshi Yamamotoya,&nbsp;Taro Saigusa,&nbsp;Hisamitsu Ishihara","doi":"10.1016/j.jdiacomp.2025.109150","DOIUrl":"10.1016/j.jdiacomp.2025.109150","url":null,"abstract":"<div><h3>Aim</h3><div>This study aimed to evaluate whether a pericardial fat pad (PFP) detected on chest X-ray can estimate metabolic dysfunction-associated steatotic liver disease (MASLD) and visceral fat accumulation.</div></div><div><h3>Methods</h3><div>Sixty-six patients with type 2 diabetes were categorized on the basis of the presence (<em>n</em> = 40) or absence (<em>n</em> = 26) of PFP on chest X-ray. The visceral fat area (VFA) and visceral-to-subcutaneous fat area ratio (V/S) at the umbilical level were assessed using abdominal computed tomography, whereas the controlled attenuation parameter (CAP) was measured using FibroScan. The fatty liver index (FLI) was estimated using clinical parameters, including body mass index (BMI), blood pressure, and biochemical markers.</div></div><div><h3>Results</h3><div>Subjects with PFP had a significantly higher BMI and a higher proportion of males. Subjects with PFP demonstrated significantly higher CAP, FLI, VFA, and V/S than those without PFP (<em>P</em> = 0.018, 0.005, &lt; 0.001, and 0.020, respectively). The cutoff values for detecting PFP on chest X-ray were CAP ≥265.5 dB/m, FLI ≥ 30.6, VFA ≥ 118.7 cm², and V/S ≥ 0.71.</div></div><div><h3>Conclusions</h3><div>In patients with type 2 diabetes, PFP detected on chest X-ray may serve as an indicator of MASLD and visceral fat accumulation.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109150"},"PeriodicalIF":3.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a link between dry eye disease and diabetes mellitus? A systematic review and meta-analysis","authors":"Kai-Yang Chen ,&nbsp;Hoi-Chun Chan ,&nbsp;Chi-Ming Chan","doi":"10.1016/j.jdiacomp.2025.109149","DOIUrl":"10.1016/j.jdiacomp.2025.109149","url":null,"abstract":"<div><h3>Background</h3><div>Keratoconjunctivitis sicca, or the dry eye disease (DED) is prevalent multifactorial disorder of the tears and ocular surface, which has lately been interested scholars, particularly in establishing its link with diabetes mellitus (DM). This study aimed to evaluate the association between DM and DED through a comprehensive systematic review and meta-analysis of existing published articles, and thus understand the attributed risks for DED development in diabetic patients.</div></div><div><h3>Methods</h3><div>Four databases, PubMed, Cochrane Library (CENTRAL), Web of Science, and Google Scholar, were electronically searched for relevant publications. Peer-reviewed articles in English language reporting on DED prevalence among diabetic population published over the last 10 years were considered. A random effect model with odds ratio (OR) and risk ratio (RR) and respective confidence intervals were used in our statistical analysis to determine pooled effect sizes.</div></div><div><h3>Results</h3><div>This study included 23 studies with 5566 participants. Diabetic individuals had a significantly higher prevalence of dry eye disease (DED) than non-diabetics (OR: 2.30 [95 % CI: 1.54–3.43]; RR: 1.69 [95 % CI: 1.28–2.25]). Older age (&gt;50 years), longer diabetes duration (&gt;10 years), and poor glycemic control (HbA1c &gt;7 %) were associated with increased DED risk. Gender-based findings varied, with slightly higher odds in males, though not statistically significant. High heterogeneity (I² = 72 %) was observed, but sensitivity analyses confirmed result stability. Minimal publication bias was detected. Mechanisms linking diabetes to DED included oxidative stress, inflammation, and neuropathy-related tear dysfunction.</div></div><div><h3>Conclusions</h3><div>Our study confirmed a significant association between DM and DED prevalence and severity, and diabetic patients exhibit higher DED risks. These risks are pronounced in older adults, particularly those diagnosed with T2DM.”. Hence, early detection and management of DED in diabetic population is a priority to enhance patient's quality of life.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109149"},"PeriodicalIF":3.1,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide and the retina: Weighing evidence against concern","authors":"Emir Muzurović ,&nbsp;Ksenija Zečević ,&nbsp;Viviana Maggio ,&nbsp;Mohamed El Tanani ,&nbsp;Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109148","DOIUrl":"10.1016/j.jdiacomp.2025.109148","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109148"},"PeriodicalIF":3.1,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The health stage of cardiovascular-kidney-metabolic (CKM) syndrome is useful for predicting all-cause mortality in patients with type 2 diabetes: a cohort study in a period prior to the standard use of recent pharmacotherapy","authors":"Keitaro Nishizawa ,&nbsp;Marenao Tanaka ,&nbsp;Tatsuya Sato ,&nbsp;Tomohito Gohda ,&nbsp;Nozomu Kamei ,&nbsp;Maki Murakoshi ,&nbsp;Yukinori Akiyama ,&nbsp;Wataru Kawaharata ,&nbsp;Hiroki Aida ,&nbsp;Hidemichi Kouzu ,&nbsp;Naoya Yama ,&nbsp;Mitsunobu Kubota ,&nbsp;Michiyoshi Sanuki ,&nbsp;Yusuke Suzuki ,&nbsp;Masato Furuhashi","doi":"10.1016/j.jdiacomp.2025.109146","DOIUrl":"10.1016/j.jdiacomp.2025.109146","url":null,"abstract":"<div><h3>Aim</h3><div>Cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined systemic condition linking cardiovascular disease, chronic kidney disease and metabolic disorders including type 2 diabetes (T2D). Although the CKM staging has been proposed for integrated risk assessment, its association with all-cause mortality in patients with T2D remains unclear. We investigated the prognosis in patients with T2D assigned by the CKM health stage.</div></div><div><h3>Methods</h3><div>A total of 632 Japanese patients with T2D were enrolled. The primary endpoint was all-cause death.</div></div><div><h3>Results</h3><div>The numbers of the recruited patients with stages 2, 3 and 4 were 353 (55.9 %), 116 (18.3 %) and 163 (25.8 %), respectively. During a median follow-up of 64 months (35,327 person-months), 62 patients (9.8 %) died. Kaplan-Meier survival curves analysis showed significant differences in cumulative mortality among CKM health stages (log-rank test: <em>P</em> &lt; 0.001) with higher cumulative mortality in stages 3 and 4 than in stage 2. Multivariable Cox proportional hazard models after adjustment of age, sex, body mass index, current smoking habit, cancer, relevant medications and hemoglobin A1c showed that adjusted hazard ratios (HRs) [95 % confidence intervals] for all-cause death were significantly higher in patients with stages 3 (2.25[1.08–4.69]) and those with stage 4 (2.87[1.41–5.84]) than in those with stage 2 as the reference. After additional adjustment of N-terminal pro-brain natriuretic peptide and estimated glomerular filtration rate among definition criteria for staging, the association of stages with all-cause death remained statistically significant in only stage 4 (2.16[1.02–4.56]).</div></div><div><h3>Conclusion</h3><div>The CKM health staging is useful for predicting all-cause mortality in Japanese patients with T2D.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109146"},"PeriodicalIF":3.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the occurrence of DKA following sodium glucose co-transporter-2 inhibitors: An international cohort study","authors":"Michael Fralick ,&nbsp;Mats C. Højbjerg Lassen ,&nbsp;Jagadish Rangrej ,&nbsp;Sahar Asgari ,&nbsp;Saad Rais ,&nbsp;Michael P. Hillmer ,&nbsp;Jamie Lee Fritz ,&nbsp;Katarina Zorcic ,&nbsp;Bruce A. Perkins ,&nbsp;Michael Colacci ,&nbsp;Tor Biering-Sørensen ,&nbsp;Muhammad Mamdani ,&nbsp;Kieran R. Campbell","doi":"10.1016/j.jdiacomp.2025.109144","DOIUrl":"10.1016/j.jdiacomp.2025.109144","url":null,"abstract":"<div><h3>Background</h3><div>Sodium glucose co-transporter 2 inhibitors (SGLT2i) are associated with a small-magnitude but higher risk of diabetic ketoacidosis (DKA). However, objectively identifying patients at lowest and highest risk of DKA is challenging.</div></div><div><h3>Methods</h3><div>We developed a prediction model using outpatient prescription data from Ontario, Canada and externally validated it using data from Denmark. We included adults with type 2 diabetes mellitus who were newly prescribed an SGLT2i. Our candidate predictors in the model were based on prior work and included the following: Sex, insulin use, prior DKA, dementia, hemoglobin A1C, and creatinine. Our outcome was 1-year risk of hospitalization with DKA. We calculated a risk score using an adaptation of penalized regression for each patient reported test characteristics in Ontario (derivation cohort) and Denmark (external validation cohort).</div></div><div><h3>Results</h3><div>We identified 322,135 in Ontario and 43,377 adults in Denmark who had type 2 diabetes mellitus and received an SGLT2i. The absolute risk of DKA within 1-year was 0.28 % (N = 916) in Ontario and 0.23 % (N = 101) in Denmark. Using data from Ontario, the risk score for each variable were as follows: Insulin use = 4 points, A1C &gt; 9 % = 4 points and prior DKA = 19 points. All other variables received zero points. The overall model AUC was 63 % in Ontario and 66 % in Denmark (external validation set). Within Ontario, at a score threshold of zero, the risk of DKA was 0.19 % and the PPV was 0.3 % and the sensitivity was 100 % and similar results were observed in Denmark. For adults with a score of 19 or higher, the risk of DKA was 35-fold higher but false positives were common yielding a PPV of 6.7 % and sensitivity was lower at 3 %. In Denmark, adults with a score of 19 or higher had a risk of 11 % and the PPV was 10.2 % and sensitivity was 5 %.</div></div><div><h3>Conclusion</h3><div>Adults with a score of 0 (that is, simply a lack of DKA history, lack of insulin therapy, and A1c &lt; 9 %) can be reassured that 99.8 % will not experience DKA in the subsequent year. In contrast, for adults with a score of 19 or higher the one-year risk of DKA is approximately 9 %, but false positives and false negatives are common and thus more work is needed to improve the predictive performance of the model.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109144"},"PeriodicalIF":3.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of imeglimin and resistance exercise improves mitochondrial function and glucose metabolism in skeletal muscles","authors":"Hajime Ishiguro ,&nbsp;Keitaro Minato ,&nbsp;Keiya Iwaasa ,&nbsp;Sijia Wu ,&nbsp;Guo Antao ,&nbsp;Takumu Tsuchida ,&nbsp;Tatsuya Suwabe ,&nbsp;Takayuki Katagiri ,&nbsp;Hiroshi Suzuki ,&nbsp;Masayoshi Masuko ,&nbsp;Ken-ichi Watanabe ,&nbsp;Takashi Ushiki ,&nbsp;Hirohito Sone","doi":"10.1016/j.jdiacomp.2025.109145","DOIUrl":"10.1016/j.jdiacomp.2025.109145","url":null,"abstract":"<div><div>The diabetes medication imeglimin, which operates through a novel mechanism of action and resistance training (RT), a significant exercise therapy, effectively enhances mitochondrial function in skeletal muscles and regulates blood glucose levels. However, the efficacy of the combination therapy remains unclear.</div><div>The combination of imeglimin and RT enhanced mitochondrial function, reduced inflammatory cytokine levels, and upregulated the expression of anti-inflammatory and antioxidant-related genes as determined by RT-PCR. Additionally, there was an increase in the protein expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1-α), a crucial regulator of mitochondrial biogenesis and glucose metabolism. This was accompanied by elevated levels of sirtuins (Sirt) 1 and 3, which positively regulate PGC1-α activity, as well as an increase in nicotinamide adenine dinucleotide (NAD⁺) levels, which are involved in Sirt1 and Sirt3 activity. Furthermore, an increase in the phosphorylation rate of protein kinase B (Akt), which plays a role in insulin signaling, and upregulation of glucose transporter type 4 (GLUT4), which is involved in glucose uptake, were observed.</div><div>These findings suggest that the combination of imeglimin and RT is a promising therapeutic approach to enhance mitochondrial function and glucose metabolic capacity.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109145"},"PeriodicalIF":3.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interplay between psychological well-being, diabetes-related distress, and glycemic control: A continuous glucose monitoring analysis from a population of adolescents with type 1 diabetes","authors":"Bruno Bombaci ,&nbsp;Stefano Passanisi ,&nbsp;Alessandro Longo ,&nbsp;Sara Aramnejad ,&nbsp;Federica Rigano ,&nbsp;Maria Cristina Marzà ,&nbsp;Tania Formica ,&nbsp;Maria Pecoraro ,&nbsp;Fortunato Lombardo ,&nbsp;Giuseppina Salzano","doi":"10.1016/j.jdiacomp.2025.109142","DOIUrl":"10.1016/j.jdiacomp.2025.109142","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to explore the relationships between glucose control, psychological well-being, and diabetes-related distress in a population of adolescents with T1D.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study on adolescents with T1D attending a Pediatric Diabetes Unit. Demographic, clinical, and glycemic data were collected, including continuous glucose monitoring (CGM) metrics. Psychological well-being was assessed using the PERMA-Profiler, while diabetes-related distress was measured using the Problem Areas in Diabetes-Teen Version (PAID-T) questionnaire.</div></div><div><h3>Results</h3><div>Among 133 enrolled adolescents, those with HbA1c ≤ 7 % exhibited significantly higher well-being scores (<em>p</em> = 0.007) and lower distress scores (<em>p</em> = 0.035). Higher time in range was positively associated with well-being (<em>p</em> = 0.002), while glycemic variability negatively impacted psychological outcomes (<em>p</em> = 0.023). Female sex (<em>p</em> = 0.021), longer disease duration (<em>p</em> = 0.022), and the absence of insulin pump therapy (<em>p</em> = 0.032) were significantly associated to higher diabetes-related distress.</div></div><div><h3>Conclusions</h3><div>Glycemic control is closely related to psychological well-being of adolescents living with T1D. The adoption of diabetes technologies may play a crucial role in reducing diabetes-related distress. Future longitudinal studies should investigate the impact of psychological interventions on CGM outcomes and overall quality of life in adolescents with T1D.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109142"},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of artificial intelligence in diabetic retinopathy screening in type 1 diabetes: A systematic review","authors":"Francesco Sacchini ,&nbsp;Stefano Mancin ,&nbsp;Giovanni Cangelosi ,&nbsp;Sara Morales Palomares ,&nbsp;Gabriele Caggianelli ,&nbsp;Francesco Gravante ,&nbsp;Fabio Petrelli","doi":"10.1016/j.jdiacomp.2025.109139","DOIUrl":"10.1016/j.jdiacomp.2025.109139","url":null,"abstract":"<div><h3>Background/objectives</h3><div>Diabetic retinopathy (DR) is one of the leading causes of blindness in adults worldwide and represents a critical complication in both type 1 (T1D) and type 2 (T2D) diabetes. Artificial Intelligence (AI) offers a promising opportunity to enhance both the accuracy of screening and the efficiency of ongoing care management, assisting healthcare providers in mitigating the incidence and complications of DR.</div></div><div><h3>Methods</h3><div>Systematic review of the literature was conducted following PRISMA guidelines. Searches were performed using PubMed-Medline, Scopus, and Embase databases, with the protocol registered on the Open Science Framework (OSF) database: (<span><span>doi.org/10.17605/OSF.IO/TJ9UH</span><svg><path></path></svg></span>). A predefined search strategy utilizing Boolean operators was applied, and two researchers independently selected articles, with a third resolving any discrepancies.</div></div><div><h3>Results</h3><div>Of the 2127 articles identified, 8 studies were included. The results highlighted that AI is particularly effective in enhancing the DR screening process in patients with T1D, offering rapid and reliable analysis. Healthcare providers reported positive feedback, noting its significant contribution to improving patient management.</div></div><div><h3>Conclusions</h3><div>The integration of AI into DR care pathways shows substantial potential for improving early diagnosis and disease management, particularly for patients with T1D. Further research is required to optimize AI implementation and ensure its positive and sustainable impact on public health.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109139"},"PeriodicalIF":3.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of colchicine on platelet aggregation in patients with type 2 diabetes: Results from a randomized placebo-controlled trial","authors":"Jonathan M. Baier ,&nbsp;Kristian L. Funck ,&nbsp;Liv Vernstrøm ,&nbsp;Søren Gullaksen ,&nbsp;Per L. Poulsen ,&nbsp;Esben Laugesen","doi":"10.1016/j.jdiacomp.2025.109141","DOIUrl":"10.1016/j.jdiacomp.2025.109141","url":null,"abstract":"<div><h3>Background</h3><div>Patients with type 2 diabetes face an increased risk of cardiovascular disease (CVD), partly due to a prothrombotic state with increased platelet reactivity. Colchicine, an anti-inflammatory drug, has shown promise in reducing cardiovascular events, but its effects on platelet function remain unclear. This trial evaluated the effect of low-dose colchicine on platelet aggregation and platelet activation indices in patients with type 2 diabetes.</div></div><div><h3>Methods</h3><div>In this double-blind, randomized, placebo-controlled trial, 100 participants with type 2 diabetes and previous CVD or a least one cardiovascular risk factor were randomized in a 1:1 ratio to receive either colchicine (0.5 mg/day) or placebo for 26 weeks. Platelet aggregation was assessed using multiple electrode aggregometry expressed as aggregation units (AU) × minutes (mins). Adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin-receptor-activating peptide (TRAP) were used as agonists.</div></div><div><h3>Results</h3><div>A total of 95 participants completed the trial. After 26 weeks, no significant differences were observed between the colchicine and placebo groups in platelet aggregation induced by ADP (ΔADP-aggregation: 49, 95 % CI: −15;113 AU x mins, <em>p</em> = 0.08), AA (ΔAA-aggregation: −4, 95 % CI: −24;16 %, <em>p</em> = 0.69), or TRAP (ΔTRAP-aggregation: −3, 95 % CI: −11;4 %, <em>p</em> = 0.39). Similarly, no between-group differences were found in platelet parameters, including platelet count mean platelet volume, and immature platelet fraction.</div></div><div><h3>Conclusions</h3><div>Low-dose colchicine did not significantly alter platelet aggregation or platelet activation indices in patients with type 2 diabetes. These findings suggest that colchicine's cardioprotective effects are not mediated through direct effects on platelet function.</div></div><div><h3>Clinical trial registration information</h3><div>EudraCT-no.: 2021-003525-30</div><div>Link: <span><span>https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003525-30/DK</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109141"},"PeriodicalIF":2.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}